Chimerix gets boost on BARDA smallpox contract extension
This article was originally published in Scrip
Executive Summary
Shares of biotech Chimerix jumped nearly 7% in morning trading on 3 June on word the US Biomedical Advanced Research and Development Authority (BARDA) extended the company's contract for another year to back development of CMX001, an experimental medical countermeasure against smallpox – providing an additional $5 million.